Avidity Partners Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$94.6M |
| 2 |
AstraZeneca
AZN
|
+$82.2M |
| 3 |
Baxter International
BAX
|
+$68.1M |
| 4 |
Caribou Biosciences
CRBU
|
+$60.5M |
| 5 |
Stevanato
STVN
|
+$59.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Maravai LifeSciences
MRVI
|
+$124M |
| 2 |
Medtronic
MDT
|
+$66.4M |
| 3 |
Biogen
BIIB
|
+$63.7M |
| 4 |
NeoGenomics
NEO
|
+$61.7M |
| 5 |
Eli Lilly
LLY
|
+$58.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.59% |
| 2 | Technology | 0.99% |
| 3 | Financials | 0.53% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Prothena Corp
PRTA
$448M
| – | – |
-182,000
| Closed | -$9.36M |
|
127
Alpha Teknova
TKNO
$273M
| – | – |
-100,000
| Closed | -$2.37M |
|
|
WKME
128
DELISTED
WalkMe Ltd. Ordinary Shares
WKME
| – | – |
-150,000
| Closed | -$4.39M |
|
|
OMIC
129
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| – | – |
-1,667
| Closed | -$1.37M |
|
|
SYNH
130
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| – | – |
-175,000
| Closed | -$15.7M |
|
|
CLVS
131
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-271,726
| Closed | -$1.58M |
|
|
TRIL
132
DELISTED
Trillium Therapeutics Inc.
TRIL
| – | – |
-4,105,000
| Closed | -$39.8M |
|
|
KDMN
133
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-9,294,600
| Closed | -$36M |
|
|
CMIIU
134
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
| – | – |
-330,000
| Closed | -$4.44M |
|
Similar funds
Avidity Partners Management's Q3 2021 Portfolio in Review
As of Q3 2021, Avidity Partners Management held 134 positions worth $4.51B, up 22% from $3.7B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Avidity Partners Management deployed $783M of net new capital in Q3 2021, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 95% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $58.1M trimmed.
- Avidity Partners Management's largest Q3 2021 buy was Regeneron Pharmaceuticals: 152,300 shares worth $92.2M.
- Avidity Partners Management added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $49.8M increase.
- Avidity Partners Management's biggest Q3 2021 reduction was Eli Lilly, cutting an estimated $58.1M.
- Avidity Partners Management fully exited Maravai LifeSciences in Q3 2021, selling an estimated $124M.
- Avidity Partners Management's ten largest holdings make up 40% of its $4.51B portfolio in Q3 2021.
- Avidity Partners Management opened 22 new positions and closed 29 in Q3 2021.
- Avidity Partners Management's portfolio value rose 22% quarter-over-quarter to $4.51B.
Based on Avidity Partners Management's 13F filing for Q3 2021, filed 15 Nov 2021.